Dilawar Ajani, MD
Internal Medicine · Houston, TXNPI 1528047115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$851
- Amgen$551
- Boehringer Ingelheim$477
- Lilly USA, LLC$404
- Sanofi-aventis U.S. LLC$403
- Novo Nordisk$397
- plus $3K from 21 others
Across 339 payments — averaging $8056.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$868K
- GSK$438K
- Endo Pharmaceuticals Inc.$279K
- Pfizer$239K
- Evofem Biosciences, Inc.$214K
- Novartis$191K
- plus $503K from 13 others
What the payments were for
- Food & beverage$5,83399%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $851 |
| Amgen | 33 | $551 |
| Boehringer Ingelheim | 29 | $477 |
| Lilly USA, LLC | 27 | $404 |
| Sanofi-aventis U.S. LLC | 22 | $403 |
| Novo Nordisk | 22 | $397 |
| Pfizer | 25 | $393 |
| Astellas Pharma US Inc | 17 | $300 |
| GSK | 16 | $287 |
| Exact Sciences | 11 | $238 |
| Amarin Pharma, Inc. | 13 | $225 |
| Merck | 14 | $221 |
| Dexcom, Inc. | 6 | $145 |
| Bayer | 6 | $129 |
| Kowa Pharmaceuticals America, Inc. | 7 | $126 |
| Sumitomo Pharma America, Inc. | 5 | $106 |
| Johnson & Johnson(2 entities) | 6 | $100 |
| Esperion Therapeutics, Inc. | 5 | $97 |
| AbbVie(2 entities) | 5 | $84 |
| Novartis | 4 | $70 |
| Azurity Pharmaceuticals, Inc. | 3 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 4 | $59 |
| Paratek Pharmaceuticals, Inc. | 1 | $30 |
| Seqirus USA Inc | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
How this compares
$5,891 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 29 | $36,776 |
| OzempicSemaglutide | 13 | $26,482 |
| JanuviaSitagliptin Phosphate | 21 | $25,986 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $25,047 |
| EliquisApixaban | 28 | $23,550 |
| VascepaIcosapent Ethyl | 46 | $21,519 |
| JardianceEmpagliflozin | 20 | $18,959 |
| TrulicityDulaglutide | 12 | $16,226 |
| LinzessLinaclotide | 17 | $13,390 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $10,996 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $9,805 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 31 | $4,686 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,184 |
| Candesartan Cilexetil | 16 | $2,287 |
| Levothyroxine Sodium | 230 | $1,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $404 | $53,00241 claims |
| MerckJanuvia, Janumet | $221 | $51,03337 claims |
| Novo NordiskOzempic | $397 | $26,48213 claims |
| PfizerEliquis | $393 | $23,55028 claims |
| Boehringer IngelheimJardiance | $477 | $18,95920 claims |
| AbbVieLinzess, Synthroid | $84 | $14,22138 claims |
| GSKTrelegy Ellipta | $287 | $9,80517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.